BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Infusional Fluorouracil and Radiation Therapy

Protocol Code: GIFUART
Tumour Group: Gastrointestinal
Contact Physician: GI Systemic Therapy

ELIGIBILITY:
- Squamous cell or Cloacogenic carcinoma of the anal canal
- T any, N any, M0
- ECOG performance status less than or equal to 2
- Adequate marrow reserve (ANC greater than or equal to 1.5 x 10^9/L, platelets greater than 100 x 10^9/L)
- Adequate renal (Creatinine less than or equal to 1.5 x ULN) and liver function (bilirubin less than or equal to 26 micromol/L; AST/Alkaline Phosphatase less than or equal to 5 x ULN)

EXCLUSIONS:
- Uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the preceding 6 months, serious uncontrolled cardiac dysrhythmia
- Known HIV positive

TESTS:
- Baseline: CBC, diff and platelets, creatinine, LFTs (Bilirubin, AST, Alkaline Phosphatase)
- During treatment: CBC, diff and platelets, weekly before chemotherapy & during radiation therapy
- If indicated clinically: bilirubin, creatinine
- For patients on warfarin, weekly INR during fluorouracil therapy until stable warfarin dose established, then INR prior to each cycle.

PREMEDICATIONS:
- Treatment is low-moderate emetogenic. See SCNAUSEA protocol.
TREATMENT:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose/m²</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>mitomycin</td>
<td>10 mg/m² on Day 1 Week 1 and Week 5 Week 5 mitomycin is optional (Maximum dose = 20 mg)</td>
<td>IV push</td>
</tr>
<tr>
<td>fluorouracil</td>
<td>1000 mg/m²/day for 4 days (Days 1-4 on Weeks 1 &amp; 5) (total dose = 4000 mg/m² over 96 h)</td>
<td>IV in D5W to a total volume of 192 mL by continuous infusion at 2 mL/h via appropriate infusor device*</td>
</tr>
</tbody>
</table>

*Inpatients: 1000 mg/m²/day in 1000 mL D5W by continuous infusion daily over 24 h for 4 days

Patients with PICC lines should have a weekly assessment of the PICC site for evidence of infection or thrombosis.

<table>
<thead>
<tr>
<th>Week</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiation therapy**</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>1/2</td>
</tr>
<tr>
<td>Infusional fluorouracil</td>
<td>X Days 1-4</td>
<td></td>
<td></td>
<td></td>
<td>X Days 1-4</td>
<td></td>
</tr>
<tr>
<td>mitomycin</td>
<td>X Day 1</td>
<td></td>
<td></td>
<td></td>
<td>X Day 1 (mitomycin optional)</td>
<td></td>
</tr>
</tbody>
</table>

** Radiotherapy: 50.4 Gy in 28 fractions (over 5 ½ weeks, no gap)

DOSE MODIFICATIONS:

1. **Hematological**

<table>
<thead>
<tr>
<th>ANC (x 10⁹/L)</th>
<th>Platelets (x 10⁹/L)</th>
<th>Dose (both drugs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater or equal than 1.5 and greater or equal than 100</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>less than 1.5 or less than 100</td>
<td>delay treatment</td>
<td></td>
</tr>
</tbody>
</table>

2. **Renal dysfunction**: Dose modification required for mitomycin if severe renal dysfunction (creatinine clearance less than 12 mL/min) (BCCA Cancer Drug Manual).

3. **Hepatic dysfunction**: Omit fluorouracil if bilirubin greater than 85 micromol/L unless secondary to biliary obstruction (BCCA Cancer Drug Manual).

PRECAUTIONS:

1. **Extravasation**: Mitomycin causes pain and tissue necrosis if extravasated out of vein. Refer to BCCA Extravasation Guidelines.

2. **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated aggressively. CBC should be checked 4-6 weeks post chemotherapy to verify that blood counts have returned to normal.

3. **Hemolytic Uremic Syndrome**: A syndrome of microangiopathic hemolytic anemia, thrombocytopenia, renal failure and hypertension has occurred in...
some patients receiving mitomycin in combination with fluorouracil. Patients treated for 6-12 months, and to cumulative doses of mitomycin greater than 50 mg/m² are at greatest risk.

4. Myocardial ischemia and angina occurs rarely in patients receiving fluorouracil or capecitabine. Development of cardiac symptoms including signs suggestive of ischemia or of cardiac arrhythmia is an indication to discontinue treatment. If there is development of cardiac symptoms patients should have urgent cardiac assessment. Generally re-challenge with either fluorouracil or capecitabine is not recommended as symptoms potentially have a high likelihood of recurrence which can be severe or even fatal. Seeking opinion from cardiologists and oncologists with expert knowledge about fluorouracil / capecitabine toxicity is strongly advised under these circumstances. The toxicity should also be noted in the patient’s allergy profile.

5. Diarrhea: Patients should report mild diarrhea that persists over 24 hours or moderate diarrhea (4 stools or more per day above normal, or a moderate increase in ostomy output). Mild diarrhea can be treated with loperamide (eg. IMODIUM®) following the manufacturer’s directions or per the BCCA Guidelines for Management of Chemotherapy-Induced Diarrhea. Note that diarrhea may result in increased INR and the risk of bleeding in patients on warfarin.

6. Dihydropyrimidine dehydrogenase (DPD) deficiency may result in severe and unexpected toxicity to fluorouracil-stomatitis, diarrhea, neutropenia, neurotoxicity-secondary to reduced drug metabolism. This deficiency is thought to be present in about 3% of the population. Fluorouracil should be permanently discontinued in patients exhibiting exaggerated or prolonged neutropenia, mucositis, and diarrhea.

7. Possible drug interaction with fluorouracil and warfarin has been reported and may occur at any time. For patients on warfarin, weekly INR during fluorouracil therapy is recommended until a stable warfarin dose is established. Thereafter, INR prior to each cycle. Consultation to cardiology/internal medicine should be considered if difficulty in establishing a stable warfarin dose is encountered. Upon discontinuation of fluorouracil, repeat INR weekly for one month.

8. Possible drug interaction with fluorouracil and phenytoin and fosphenytoin has been reported and may occur at any time. Close monitoring is recommended. Fluorouracil may increase the serum concentration of these two agents.

Call the GI Systemic Therapy physician at your regional cancer centre or Dr. JP McGhie at (250) 519-5500 or 1-800-670-3322 with any problems or questions regarding this treatment program.

Date activated: N/A (as GIFUA)
Date revised: 1 Nov 2015 (addition of Diarrhea Precaution)
REFERENCES:
